Last Update Time:
05-Feb-2025 09:36:15
ISIN:
INE044A01036
Sector:
Healthcare
Symbol:
SUNPHARMA
Sun Pharmaceutical Industries Limited
₹1,753.50
₹-11.75
(-0.67%)
▼
Prev. Close
₹1,765.25
Open
₹1,773.80
Close
₹0.00
Range
₹1,665.83 - ₹1,841.18
High
₹1,773.80
Low
₹1,745.40
Ind. Close
₹0.00
VWAP
₹1,755.54
The current stock price of Sun Pharmaceutical Industries Limited is ₹1,753.50, with a target price range between ₹1,665.83 and ₹1,841.18. The stock has experienced a price change of ₹-11.75 (-0.67%), reflecting recent market volatility.
Today's opening price was ₹1,773.80, while the previous close stood at ₹1,765.25. The intraday high reached ₹1,773.80, and the low touched ₹1,745.40. The volume-weighted average price (VWAP) is currently ₹1,755.54, indicating the stock's average traded price.
The market trend suggests a potential downtrend, with investors exercising caution due to recent declines. Analysts recommend closely monitoring support levels.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Sun Pharmaceutical Industries Limited Price Chart
Sun Pharmaceutical Industries Limited Pre Open Market Overview: 05-Feb-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 1773.8
- Previous Close Price: 1765.25
- Change: 8.55%
- Total Traded Volume: 5,822
- Total Buy Quantity: 4,855
- Total Sell Quantity: 27,352
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 1,765.45 | 285.00 | 0.00 |
| 1,765.50 | 500.00 | 0.00 |
| 1,768.00 | 2.00 | 0.00 |
| 1,770.00 | 10.00 | 0.00 |
| 1,771.05 | 5.00 | 0.00 |
| 1,773.80 | 0.00 | 104.00 |
| 1,773.95 | 0.00 | 3.00 |
| 1,774.00 | 0.00 | 801.00 |
| 1,775.00 | 0.00 | 130.00 |
| 1,777.00 | 0.00 | 2.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 1,753.20 | 5 | 1,754.00 | 54 |
| 1,753.10 | 9 | 1,754.05 | 59 |
| 1,753.05 | 35 | 1,754.10 | 17 |
| 1,753.00 | 96 | 1,754.15 | 12 |
| 1,752.85 | 37 | 1,754.20 | 36 |
Total Buy Quantity: 92,790
Total Sell Quantity: 94,990
Shareholding Patterns (in %) of Sun Pharmaceutical Industries Limited
| Category | 31-Dec-2023 | 31-Mar-2024 | 30-Jun-2024 | 30-Sep-2024 | 31-Dec-2024 |
|---|---|---|---|---|---|
| Promoter & Promoter Group | 54.48 | 54.48 | 54.48 | 54.48 | 54.48 |
| Public | 45.52 | 45.52 | 45.52 | 45.52 | 45.52 |
| Shares held by Employee Trusts | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
Key Trade Statistics of Sun Pharmaceutical Industries Limited
The trade information for Sun Pharmaceutical Industries Limited includes a total traded volume of 1.73 lakh shares, and a traded value of ₹30.39 crore.
The market cap is ₹420,723.39 crore, with a free float market cap of ₹189,169.14 crore. The deliverable quantity is 1,758,794.00 shares, reflecting 62.9% of total trades.
Key risk indicators include security VaR at 7.51% and an applicable margin rate of 12.5%.
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 1.73 |
| Traded Value (₹ Cr.) | 30.39 |
| Total Market Cap (₹ Cr.) | 420,723.39 |
| Free Float Market Cap (₹ Cr.) | 189,169.14 |
| Impact cost | 0.02 |
| Quantity Traded | 2,796,294.00 |
| Deliverable Quantity | 1,758,794.00 |
| % of Quantity to Traded | 62.9 |
| Security VaR | 7.51 |
| Index VaR | N/A |
| VaR Margin | 9 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 12.5 |
| Face Value | 1 |
Key Price Statistics of Sun Pharmaceutical Industries Limited
The 52-week high for Sun Pharmaceutical Industries Limited was ₹1,960.35, recorded on 30-Sep-2024. On the other hand, the 52-week low stands at ₹1,377.20, with the lowest value recorded on 04-Jun-2024.
The upper band for trading is ₹N/A, and the lower band is ₹N/A. The price band is No Band%.
The stock's daily volatility stands at 1.21, while the annualized volatility is 23.12. The tick size for trading is ₹N/A.
| Price Information | Details |
|---|---|
| 52 Week High (30-Sep-2024) | 1,960.35 |
| 52 Week Low (04-Jun-2024) | 1,377.20 |
| Upper Band | 1,941.75 |
| Lower Band | 1,588.75 |
| Price Band (%) | No Band |
| Daily Volatility | 1.21 |
| Annualised Volatility | 23.12 |
| Tick Size | 0.05 |
Key Securities Statistics of Sun Pharmaceutical Industries Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 08-Feb-1995 |
| Adjusted P/E | 35.75 |
| Symbol P/E | 36.87 |
| Index | NIFTY 50 |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Sun Pharmaceutical Industries Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Sun Pharmaceutical Industries Limited
| Subject | Date |
|---|---|
| Action(s) taken or orders passed | 04-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 04-Feb-2025 |
| Press Release | 04-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 04-Feb-2025 |
| Updates | 03-Feb-2025 |
| Updates | 03-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 31-Jan-2025 |
| Integrated Filing- Financial | 31-Jan-2025 |
Corporate Actions of Sun Pharmaceutical Industries Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 1 | Interim Dividend - Rs 10.50 Per Share | 06-Feb-2025 |
| 1 | Dividend - Rs 5 Per Share | 12-Jul-2024 |
| 1 | Interim Dividend - Rs 8.50 Per Share | 09-Feb-2024 |
| 1 | Dividend - Rs 4 Per Share | 28-Jul-2023 |
| 1 | Interim Dividend - Rs 7.50 Per Share | 08-Feb-2023 |
| 1 | Dividend - Rs 3 Per Share | 19-Aug-2022 |
| 1 | Interim Dividend - Rs 7 Per Share | 09-Feb-2022 |
| 1 | Annual General Meeting/Dividend - Rs 2 Per Share | 23-Aug-2021 |
| 1 | Interim Dividend - Rs 5.50 Per Share | 09-Feb-2021 |
| 1 | Annual General Meeting/Dividend - Re 1 Per Share | 19-Aug-2020 |
| 1 | Interim Dividend - Rs 3 Per Share | 17-Feb-2020 |
| 1 | Annual General Meeting/Dividend - Rs 2.75 Per Share | 20-Aug-2019 |
| 1 | Annual General Meeting/Dividend Rs 2 Per Share | 17-Sep-2018 |
| 1 | Annual General Meeting/Dividend - Rs 3.50 Per Share | 18-Sep-2017 |
| 1 | Annual General Meeting/Dividend Re 1/- Per Share | 08-Sep-2016 |
| 1 | Buy Back | 14-Jul-2016 |
| 1 | Annual General Meeting/ Dividend - Rs 3/- Per Share | 21-Oct-2015 |
| 1 | Annual General Meeting / Dividend - Rs 1.50/- Per Share | 11-Sep-2014 |
| 1 | Annual General Meeting / Dividend - Rs 2.50/- Per Share | 19-Sep-2013 |
| 1 | Bonus 1:1 | 29-Jul-2013 |
Board Meetings of Sun Pharmaceutical Industries Limited
Financial Results of Sun Pharmaceutical Industries Limited
| Qtr Ended | Tot. Income | Net P/L | EPS | Notes |
|---|---|---|---|---|
| 31 Dec 2024 | 626,020 | 118,105 | 4.9 | |
| 30 Sep 2024 | 521,401 | 86,329 | 3.6 | |
| 30 Jun 2024 | 458,081 | 23,782 | 1 | |
| 31 Mar 2024 | 575,802 | 86,760 | 3.6 | |
| 31 Dec 2023 | 515,055 | 72,131 | 3 |
Company Directory of Sun Pharmaceutical Industries Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| www.sunpharma.com | Head Office/ Corporate Office | SUN HOUSE Plot No. 201 B/1 Western Express Highway Goregaon (East) | MUMBAI |
| www.sunpharma.com | Registered Office | SPARC, Tandalja | VADODARA |
| www.sunpharma.com | Transfer Agent | Link Intime India Private Limited C- 101, 1st Floor, 247 Park Lal Bahadur Shastri Marg Vikhroli (West) | MUMBAI |
Insider Trading of Sun Pharmaceutical Industries Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | RAKSHA VALIA-Person Acting in Concert and immediate relative of Non Executive Non Independent Director (Member of Promoter Group) | 2256340000 | Pledge |
| 7(2) | RAKSHA VALIA-Person Acting in Concert and immediate relative of Non Executive Non Independent Director (Member of Promoter Group) | 937450000 | Pledge |
| 7(2) | ADITYA MEDISALES LIMITED | 5893860500 | Pledge Revoke |
| 7(2) | RAKSHA VALIA-Person Acting in Concert and immediate relative of Non Executive Non Independent Director (Member of Promoter Group) | 1585980000 | Pledge |
| 7(2) | Sailesh T. Desai | 3862970 | Sell |
| 7(2) | Shanghvi Finance Private Limied | 115672664 | Pledge Revoke |
| 7(2) | RAKSHA VALIA-Person Acting in Concert and immediate relative of Non Executive Non Independent Director (Member of Promoter Group) | 1121604000 | Pledge |
| 7(2) | RAKSHA VALIA-Person Acting in Concert and immediate relative of Non Executive Non Independent Director (Member of Promoter Group) | 7771289300 | Pledge Revoke |
| 7(2) | RAKSHA VALIA-Person Acting in Concert and immediate relative of Non Executive Non Independent Director (Member of Promoter Group) | 1152574500 | Pledge |
| 7(2) | RAKSHA VALIA-Person Acting in Concert and immediate relative of Non Executive Non Independent Director (Member of Promoter Group) | 2343891000 | Pledge |
| 7(2) | Sailesh T. Desai | 14947500 | Pledge Revoke |
| 7(2) | ADITYA MEDISALES LIMITED | 6141000000 | Pledge |
| 7(2) | RAKSHA VALIA-Person Acting in Concert and immediate relative of Non Executive Non Independent Director (Member of Promoter Group) | 3000150000 | Pledge |
| 7(2) | Sailesh T. Desai | 2050000 | Sell |
| 7(2) | Sailesh T. Desai | 5140678 | Sell |
| 7(2) | Sailesh T. Desai | 2043186 | Sell |
| 7(2) | RAKSHA VALIA-Person Acting in Concert and immediate relative of Non Executive Non Independent Director (Member of Promoter Group) | 452520000 | Pledge |
| 7(2) | PRITI GANDHI | 3090000 | Sell |
| 7(2) | Nilesh Gandhi | 2057080 | Sell |
| 7(2) | RAKSHA VALIA-Person Acting in Concert and immediate relative of Non Executive Non Independent Director (Member of Promoter Group) | 62400000 | Pledge Revoke |
Annual Reports of Sun Pharmaceutical Industries Limited
Investor Complaints of Sun Pharmaceutical Industries Limited
| Date | Pending | Received | Disposed | Unresolved |
|---|---|---|---|---|
| 30-Sep-2024 | 5 | 15 | 20 | 0 |
| 30-Jun-2024 | 0 | 10 | 5 | 5 |
| 31-Mar-2024 | 0 | 20 | 20 | 0 |
| 31-Dec-2023 | 1 | 10 | 11 | 0 |
| 30-Sep-2023 | 0 | 8 | 7 | 1 |
| 30-Jun-2023 | 0 | 8 | 8 | 0 |
| 31-Mar-2023 | 1 | 12 | 13 | 0 |
| 31-Dec-2022 | 1 | 6 | 6 | 1 |
| 30-Sep-2022 | 0 | 8 | 7 | 1 |
| 30-Jun-2022 | 0 | 8 | 8 | 0 |
| 31-Mar-2022 | 1 | 1 | 2 | 0 |
| 31-Dec-2021 | 0 | 1 | 0 | 1 |
| 30-Sep-2021 | 0 | 0 | 0 | 0 |
| 30-Jun-2021 | 0 | 1 | 1 | 0 |
| 31-Mar-2021 | 0 | 0 | 0 | 0 |
| 31-Dec-2020 | 0 | 1 | 1 | 0 |
| 30-Sep-2020 | 0 | 1 | 1 | 0 |
| 30-Jun-2020 | 0 | 0 | 0 | 0 |
| 31-Mar-2020 | 0 | 1 | 1 | 0 |
| 31-Dec-2019 | 0 | 1 | 1 | 0 |
| 30-Sep-2019 | 0 | 1 | 1 | 0 |
| 30-Jun-2019 | 0 | 0 | 0 | 0 |
| 31-Mar-2019 | 0 | 1 | 1 | 0 |
| 31-Dec-2018 | 0 | 0 | 0 | 0 |
| 30-Sep-2018 | 0 | 0 | 0 | 0 |
| 30-Jun-2018 | 0 | 0 | 0 | 0 |
| 31-Mar-2018 | 0 | 2 | 2 | 0 |
| 31-Dec-2017 | 0 | 0 | 0 | 0 |
| 30-Sep-2017 | 0 | 0 | 0 | 0 |
| 30-Jun-2017 | 0 | 1 | 1 | 0 |
| 31-Mar-2017 | 0 | 1 | 1 | 0 |
Event Calendar of Sun Pharmaceutical Industries Limited
| Purpose | Details |
|---|---|
| Demerger | Interalia, to consider the proposal for demerger of the Company's Innovative Research and Development (including new drug delivery systems) undertaking to a new company. |
| Results/Dividend | Interalia, (1) To consider and approve the audited financial results of the Company for the year ended March 31, 2010. (2) To consider recommendation of payment of dividend on equity shares for the year ended March 31, 2010 subject to the approval of the shareholders at the ensuing Annual General Meeting. |
| Results/Dividend | Inter alia (1) To consider and approve the audited financial results of the Company for the year ended March 31, 2011. (2) To consider the recommendation of payment of Dividend on equity shares for the year ended March 31, 2011 subject to the approval of the shareholders at the ensuing Annual General Meeting. |
| Results/Dividend | Interalia, (1) To consider and approve the audited financial results of the Company for the year ended March 31, 2012; (2) To consider the recommendation of payment of dividend on equity shares for the year ended March 31, 2012, subject to the approval of the shareholders at the ensuing Annual General Meeting. |
| Results/Dividend | The Company had informed the Exchange regarding a Board meeting to be held on August 10, 2012 interalia, to consider and take on record the un-audited financial results of the Company for the first quarter ended June 30, 2012. The Company has now informed the Exchange that Board meeting to be held on August 10, 2012 to consider the quarterly unaudited results of the Company interalia, the following additional agenda items also would be considered : (i) To consider the internal restructuring of the business of the Company with effect from March 31,2012. (ii) To consider declaration of the interim dividend of Rs.4.25 per Share of Re.1 each on Equity Shares of the Company for the year ended March 31, 2012 in lieu of the earlier recommended proposed dividend of Rs.4.25 per Share of Re.1 each on Equity Shares of the Company for the year ended March 31, 2012 in view of the likely delay for the redrawing and audit of the revised accounts for the year ended March 31, 2012 and adoption of accounts by the members due to the proposed restructuring of the business of the Company with effect from March 31,2012, if the Board approves the proposed restructuring. (Purpose Revised) |
| Results | Inter-alia, to consider and take on record the un-audited financial results of the Company for the third quarter ended December 31, 2012. |
| Results | Interalia, to consider and take on record un-audited financial results of the Company for the third quarter ended December 31, 2012. |
| Scheme of Arrangement | The Company has informed that the Hon'ble High Court of Gujarat, at Ahmedabad and Hon'ble High Court of Mumbai, at their respective hearing held both on May 03, 2013 approved the Scheme of Arrangement between Sun Pharmaceutical Industries Limited (SPIL) and Sun Pharma Laboratories Limited (SPLL) in the nature of Spin-Off and transfer of Domestic Formulation Business/Undertaking of SPIL to SPLL with effect from the appointed date of March 31, 2012. Further, the Company has informed that the certified copies of the High Court orders will be filed with the Registrar of Companies shortly as required and the spin off process would get completed. Further, in view thereof, the Board of Directors of the Company would also consider the revised audited annual accounts of the Company for the year ended March 31, 2012 after giving the effect to the above mentioned Scheme of Arrangement between SPIL and SPLL (along with the consideration of audited annual accounts of the Company for the year ended March 31, 2013) at their meeting to be held on May 28, 2013. |
| Results/Dividend | Interalia, (1) To consider and approve the audited financial results of the Company for the year ended March 31, 2013; (2) To consider the recommendation of payment of dividend for the year ended March 31, 2013, subject to the approval of the shareholders at the ensuing Annual General Meeting. |
| Results | Interalia, to consider and take on record the un-audited financial results of the Company for the first quarter ended June 30, 2013 |
| Results | Interalia, to consider and take on record the un-audited financial results of the Company for the second quarter / half year ended September 30, 2013. |
| Results | Interalia, to consider and take on record the un-audited financial results of the Company for the third quarter ended December 31, 2013. |
| Results/Others | inter alia, to consider and approve the audited financial results of the Company stand alone and consolidated for the year ended March 31, 2014. The said audited results are subject to revision so as to give effect of demerger with effect from May 01, 2013 of the Specified Undertaking of Sun Pharma Global FZE, the Company's wholly owned subsidiary company with the Company, after receipt of all required approvals from the statutory authorities in respect of the demerger. Further, note that window closure for Trading by Designated persons as per Insider Trading Rules of the Company will be from May 20, 2014 to June 02, 2014 (both days inclusive). |
| Results/Others | Inter alia, to consider and approve the audited financial results of the Company stand alone and consolidated for the year ended March 31, 2014. The said audited results are subject to revision so as to give effect of demerger with effect from May 01, 2013 of the Specified Undertaking of Sun Pharma Global FZE, the Company's wholly owned subsidiary company with the Company, after receipt of all required approvals from the statutory authorities in respect of the demerger. Further, note that window closure for Trading by Designated persons as per Insider Trading Rules of the Company will be from May 20, 2014 to June 02, 2014 (both days inclusive). |
| Results/Dividend | The Board of Directors of the Company would meet on August 12, 2014 to transact, inter alia, the following business. (i) Consider the revised audited annual accounts of the Company for the year ended March 31, 2014 after giving the effect to the above mentioned Scheme of Arrangement and Reconstruction between SPIL and SPGFZE. (ii) To consider the recommendation of payment of dividend on equity shares for the year ended March 31, 2014 subject to the approval of the shareholders at the ensuing Annual General Meeting. (iii) To consider and take on record the un-audited financial results of the Company for the first quarter ended June 30, 2014 (Q1). The window closure for Trading by Designated persons as per Insider Trading Rules of the Company will be from August 01, 2014 to August 14, 2014 (both days inclusive). |
| Results | inter alia, to consider and take on record the un-audited financial results of the Company for the second quarter ended September 30, 2014. |
| Results | Inter alia, to consider and take on record the Unaudited Financial Results of the Company for the third quarter and nine months ended December 31, 2014. |
| Results/Others | Interalia to consider and approve the audited financial results of the Company stand alone and consolidated for the year ended March 31, 2015. The said audited results are subject to revision so as to give effect of amalgamation of Sun Pharma Global Inc, our wholly owned subsidiary company, with the Company with effect from January 1, 2015, after receipt of all required approvals from the statutory authorities in respect of the amalgamation. |
| Results | Interalia, to consider and take on record the Unaudited Financial Results of the Company for the first quarter and three months ended June 30, 2015. |
| Results/Dividend | Sun Pharmaceuticals Industries Limited had informed the Exchange that the meeting of the Board of Directors of the Company will be held on August 11, 2015, Interalia, to consider and take on record the Unaudited Financial Results of the Company for the first quarter and three months ended June 30, 2015.The Company has now informed the Exchange that the Hon'ble High Court of Gujarat, at Ahmedabad at its hearing held on July 30, 2015 has approved the Scheme of Amalgamation of Sun Pharma Global Inc. (SPGI), wholly-owned subsidiary of the Company, into Sun Pharmaceutical Industries Limited (SPIL) with effect from the appointed date of January 1, 2015. This is to further inform you that the certified copy of the High Court order is expected to be received shortly and will be filed with the Registrar of Companies there after as required and the process of merger would get completed on such filing.The Board of Directors of the Company at its meeting scheduled to be held on August 11, 2015 would also transact the following business:(i) Consideration of the revised audited annual accounts of the Company for the year ended 31st March, 2015 after giving the effect to the above mentioned Scheme of Amalgamation of SPGI into SPIL and the proposal for payment of dividend.(ii) Consideration of the recommendation of payment of dividend on equity shares for the year ended March 31, 2015 subject to the approval of the shareholders at the ensuing Annual General Meeting. |
| Results | Interalia, to consider and take on record the Unaudited Financial Results of the Company for the second quarter and six months ended September 30, 2015. |
| Results/Others | interalia, to consider and take on record the Unaudited Financial Results of the Company for the Third quarter and nine months ended December 31, 2015. |
| Results/Dividend | interalia, to transact the following business :(i) To consider and approve standalone and consolidated Audited Financial Results of the Company for the year ended March 31, 2016.(ii) To consider recommendation of dividend for the year ended March 31, 2016 subject to the approval of the shareholders at the ensuing Annual General Meeting. |
| Buyback | For evaluating a proposal of Buy Back of Equity Shares of the Company. |
| Results | interalia, to consider and take on record the Unaudited Financial Results of the Company for the quarter ended June 30, 2016. |
| Results/Others | To transact, interalia, the following business: a. To consider and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2016.b. To consider the proposal for the merger/amalgamation of Ranbaxy Drugs Limited, Vidyut Investments Limited, Gufic Pharma Limited and Sun Pharma Medisales Private Limited (formerly known as Solrex Pharmaceutical Company), all four companies being wholly owned subsidiaries of Sun Pharmaceutical Industries Ltd., with Sun Pharmaceutical Industries Ltd subject to receipt of necessary approvals. In view of the consideration of above items, the window closure for trading by designated persons as per Insider Trading Rules of the Company will be from November 1, 2016 to November 14, 2016 (both days inclusive). |
| Results | To consider and take on record the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2016. |
| Results/Dividend | Interalia, to transact the following business : (i) To consider and approve standalone and consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2017. (ii) To consider recommendation of dividend for the year ended March 31, 2017 subject to the approval of the shareholders at the ensuing Annual General Meeting. |
| Results | To consider and take on record the Unaudited Financial Results of the Company for the quarter ended June 30, 2017. |
| Results | to consider and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2017. |
| Results | To consider and take on record, the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2017. |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2018 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2018. Notice of Board Meeting for consideration and approval of Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2018 and intimation of dates of Window Closure for Trading by Designated persons. |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2018 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2019 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2019 |
| Financial Results | To inter alia consider and approve the financial results for the period ended December 31, 2019 |
| Dividend | Consider declaration of Interim Dividend on the equity shares of the Company, for the Financial Year 2019-2020. |
| Buyback | To consider, inter alia, the proposal for buy-back of fully paid-up equity shares of the Company, which would include maximum amount, maximum number of equity shares, mode of buy-back and other matters incidental thereto in accordance with the provisions of Section 68, 69 and 70 of the Companies Act,2013, read with rules made thereto and Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018.In this connection, as per the Company's code of conduct for prevention of insider trading, the trading window for dealing or trading in securities of the Company will remain closed with immediate effect for all directors, designated persons and insiders and shall re-open after the expiry of 48 hours after the conclusion of the aforesaid Board Meeting.proposal buyback for equity shares |
| Financial Results/Dividend | To consider and approve Audited Standalone and Consolidated Financial Results of the Company for the fourth quarter and year ended March 31, 2020 and to consider recommendation of final dividend for the year ended March 31, 2020 subject to the approval of the shareholders at the ensuing Annual General Meeting. |
| Financial Results | To consider and approve the Unaudited Standalone and Consolidated Financial Results financial results for the quarter ended Jun 30, 2020 |
| Financial Results | To consider and approve the Unaudited Standalone and Consolidated financial results of the Company for the quarter and half year ended September 30, 2020 |
| Financial Results | To consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2020 |
| Financial Results/Dividend | To consider and approve the audited financial results for the quarter and year ended March 31, 2021 and recommendation of final dividend for the year ended March 31, 2021. |
| Financial Results | To consider and approve the Unaudited Standalone and Consolidated financial results for the quarter ended Jun 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2021 |
| Financial results | Sun Pharmaceutical Industries Limited has informed the Exchange about Board Meeting to be held on 29-Jul-2022 to consider financial statements for the period ended June 2022 |
| Financial results | Sun Pharmaceutical Industries Limited has informed the Exchange about Board Meeting to be held on 01-Nov-2022 to consider financial statements for the period ended September 2022 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2022 and consider interim dividend |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2023 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2023 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2023 and interim dividend |
| Financial Results/Dividend | To consider and approve the audited financial results for the period ended March 31, 2024 and final dividend |
| Financial Results | To consider and approve Quarterly Financial Results for Q1 of FY 2024-25 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2024 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2024 and Interim dividend for FY 2024-25 |
Share Transfers of Sun Pharmaceutical Industries Limited
Voting Results of Sun Pharmaceutical Industries Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 21-JAN-2025 | Court Convened Meeting | To consider and approve the Composite Scheme of Arrangement for amalgamation of five wholly-owned subsidiaries with the Company and Reclassification of general reserves into retained earnings |
| 21-JAN-2025 | Court Convened Meeting | To consider and approve the Composite Scheme of Arrangement for amalgamation of five wholly-owned subsidiaries with the Company and Reclassification of general reserves into retained earnings |
| 05-AUG-2024 | AGM | Adoption of audited standalone financial statements of the Company for the financial year ended March 31, 2024 and the reports of the Board of Directors and Auditors thereon. |
| 05-AUG-2024 | AGM | Approval for material related party transaction between Taro Pharmaceuticals Inc, Canada and Taro Pharmaceuticals USA, Inc for the financial year 2024-25. |
| 05-AUG-2024 | AGM | Approval for material related party transactions between Taro Pharmaceuticals Industries Limited, Israel and Taro Pharmaceuticals USA, Inc for the financial year 2024-25. |
| 05-AUG-2024 | AGM | Ratification of the remuneration of the Cost Auditors for financial year 2024-25. |
| 05-AUG-2024 | AGM | Appointment of Mr. Dilip Shanghvi (DIN: 00005588) as a Director, who retires by rotation. |
| 05-AUG-2024 | AGM | Declaration of final dividend of Rs. 5 (Rupees Five only) per Equity Share of Re. 1 (Rupee one only) for the financial year 2024-25 |
| 05-AUG-2024 | AGM | Adoption of audited consolidated financial statements of the Company for the financial year ended March 31, 2024 and the report of the Auditors thereon. |
| 10-MAY-2024 | Postal Ballot | Proposed Material Related Party Transaction between Alkaloida Chemical Company ZRT (￢ﾀﾜAlkaloida￢ﾀﾝ) and Libra Merger Limited (￢ﾀﾜLibra￢ﾀﾝ), subsidiaries of the Company, involving infusion of capital of an amount not exceeding USD 348 million (equivalent to INR 2,894.2 Crore approx.) by Alkaloida into Libra during the financial year 2024-25. |
| 28-AUG-2023 | AGM | Adoption of Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2023, and the reports of the Board of Directors and Auditors thereon. |
| 28-AUG-2023 | AGM | Approval of material related party transactions for purchase and sale of pharmaceutical products between Taro Pharmaceuticals USA, Inc and Taro Pharmaceuticals Inc., Canada, both non-wholly owned subsidiaries of the Company, for the financial year 2023-24, not exceeding an aggregate value equivalent to Rs. 20,000 Million. |
| 28-AUG-2023 | AGM | Approval of Appointment and remuneration of Mr. Aalok Shanghvi (DIN: 01951829) as the Whole-time Director of the Company for a term of 5 years effective from June 01, 2023 to May 31, 2028. |
| 28-AUG-2023 | AGM | Approval of Appointment of Mr. Rolf Hoffmann (DIN: 10200311) as an Independent Director of the Company from a term of 5 years effective from June 15, 2023 to June 14, 2028. |
| 28-AUG-2023 | AGM | Ratification of remuneration to M/s. K D & Co, Cost Accountants, the Cost Auditors for financial year 2023-24. |
| 28-AUG-2023 | AGM | Re-appointment of Mr. Sudhir Valia (DIN: 00005561), who retires by rotation, and being eligible, had offered himself for re-appointment as a Director. |
| 28-AUG-2023 | AGM | Declaration of Final Dividend of Rs. 4/- per equity share, for the financial year 2022-23. |
| 28-AUG-2023 | AGM | Adoption of the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2023 and the report of the Auditors thereon. |
| 27-JAN-2023 | Postal Ballot | Appointment of Mr. Sanjay Asher (DIN: 00008221) as an Independent Director of the Company |
| 29-AUG-2022 | AGM | Adoption of Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2022, and the reports of the Board of Directors and Auditors thereon. |